PMID- 15030287
OWN - NLM
STAT- MEDLINE
DCOM- 20040423
LR  - 20051116
IS  - 1477-9072 (Print)
IS  - 1477-9072 (Linking)
VI  - 1
IP  - 2
DP  - 2003 Jul
TI  - Antithrombotics in thrombosis and cancer.
PG  - 283-91
AB  - Many cancer patients reportedly are in a hypercoaguable state, with recurrent 
      thrombosis due to the impact of cancer cells and chemotherapy or radiotherapy on 
      the coagulation cascade. Studies have demonstrated that unfractionated heparin 
      (UFH) or low-molecular-weight heparin (LMWH) interfere with various processes 
      involved in tumor growth and metastasis. These include fibrin formation, binding 
      of heparin to angiogenic growth factors such as basic fibroblast growth factor 
      and vascular endothelial growth factor, modulation of tissue factor and, perhaps, 
      other more important modulatory mechanisms such as enhanced tissue factor pathway 
      inhibitor (TFPI) release and inhibition of various matrix-degrading enzymes. 
      Clinical trials have suggested a clinically relevant effect of LMWH, compared 
      with UFH on the survival of cancer patients with deep vein thrombosis. Similarly, 
      the impact of warfarin on the survival of cancer patients with thromboembolic 
      disorders was demonstrated. Studies from our laboratory demonstrated a 
      significant role for LMWH, warfarin, anti-VIIa and LMWH-releasable TFPI on the 
      regulation of angiogenesis, tumor growth, and tumor metastasis. Thus, modulation 
      of tissue factor/VIIa noncoagulant activities by LMWH, warfarin, anti-VIIa or 
      TFPI might be a useful therapeutic option for the inhibition of angiogenesis 
      associated with human tumor growth and metastasis.
FAU - Mousa, Shaker A
AU  - Mousa SA
AD  - Albany College of Pharmacy, NY 12208-3492, USA. mousas@acp.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Cardiovasc Ther
JT  - Expert review of cardiovascular therapy
JID - 101182328
RN  - 0 (Anticoagulants)
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - Anticoagulants/therapeutic use
MH  - Blood Coagulation/drug effects/physiology
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Neoplasms/blood/*drug therapy
MH  - Neovascularization, Pathologic/blood/drug therapy
MH  - Platelet Activation/drug effects/physiology
MH  - Thrombosis/blood/*drug therapy
RF  - 66
EDAT- 2004/03/20 05:00
MHDA- 2004/04/24 05:00
CRDT- 2004/03/20 05:00
PHST- 2004/03/20 05:00 [pubmed]
PHST- 2004/04/24 05:00 [medline]
PHST- 2004/03/20 05:00 [entrez]
AID - ERC010213 [pii]
AID - 10.1586/14779072.1.2.283 [doi]
PST - ppublish
SO  - Expert Rev Cardiovasc Ther. 2003 Jul;1(2):283-91. doi: 10.1586/14779072.1.2.283.